Linzagolix: eine neue Therapieoption bei Adenomyosis uteri

In: Geburtshilfe und Frauenheilkunde · 2020 · vol. 80(12) , pp. 1165–1166 · doi:10.1055/a-1265-7850 · W4231332476
Case report OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Linzagolix, a novel therapy, is presented as an option for women suffering from uterine adenomyosis, a condition affecting approximately 20% of fertile women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-17 · read from full text ⓘ

This article reviews the potential of linzagolix as a therapeutic option for adenomyosis uteri, a condition affecting approximately 20% of women of reproductive age and characterized by heavy menstrual bleeding, pelvic pain, and infertility. The authors discuss a case report involving a patient who responded differently to two distinct antihormonal treatments, highlighting the variability in clinical outcomes. The text positions linzagolix within the context of managing this specific uterine pathology based on emerging evidence from international research. This paper is centrally about adenomyosis — specifically evaluating linzagolix as a new hormonal treatment modality for the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Etwa 20% der Frauen im fertilen Alter leiden an einer Adenomyosis uteri. Je nach Schweregrad verursacht diese Uteruspathologie Hypermenorrhöen, Unterbauchschmerzen sowie Infertilität. Zwei Wissenschaftler aus Frankreich und Belgien beschreiben den Fall einer betroffenen Frau, welche auf 2 verschiedene antihormonelle Therapieversuche unterschiedlich gut angesprochen hatte.
Full text 874 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS Please copy the URL and add it into your RSS Feed Reader. https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml Geburtshilfe Frauenheilkd 2020; 80(12): 1165-1166 DOI: 10.1055/a-1265-7850 DOI: 10.1055/a-1265-7850 GebFra Magazin Aktuell referiert Linzagolix: eine neue Therapieoption bei Adenomyosis uteri Etwa 20% der Frauen im fertilen Alter leiden an einer Adenomyosis uteri. Je nach Schweregrad verursacht diese Uteruspathologie Hypermenorrhöen, Unterbauchschmerzen sowie Infertilität. Zwei Wissenschaftler aus Frankreich und Belgien beschreiben den Fall einer betroffenen Frau, welche auf 2 verschiedene antihormonelle Therapieversuche unterschiedlich gut angesprochen hatte. Publication History Article published online: 03 December 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK